These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32562825)

  • 21. [AL Amyloidosis].
    Ueda M
    Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.
    Karam S; Leung N
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1069-1079. PubMed ID: 33099424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.
    Palladini G; Liedtke M; Zago W; Dolan P; Kinney GG; Gertz MA
    Leuk Lymphoma; 2024 Aug; 65(8):1068-1078. PubMed ID: 38600883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
    Saith SE; Maurer MS; Patel AR
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coexistence of amyloidosis and light chain deposition disease in the heart.
    Sobue Y; Takemura G; Kawamura S; Yano T; Kanamori H; Morimoto SI; Matsuo H
    Cardiovasc Pathol; 2021; 51():107315. PubMed ID: 33264681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
    Wang J; Li J; Zhong L
    Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localized Lymph Node Light Chain Amyloidosis.
    Yamamoto A; Fujii N; Obika M; Yamashita T; Otsuka F
    Intern Med; 2020 Oct; 59(19):2415-2418. PubMed ID: 32611959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
    Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Amyloidosis due to Low-Grade Lymphoma.
    Wechalekar AD; Chakraborty R; Lentzsch S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1027-1039. PubMed ID: 33099421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
    Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
    Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
    Gertz MA
    Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.
    Alkhawam H; Patel D; Nguyen J; Easaw SM; Al-Sadawi M; Syed U; Zaiem F; Homsi M; Vittorio TJ
    Acta Cardiol; 2017 Aug; 72(4):380-389. PubMed ID: 28705053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies gone bad - the molecular mechanism of light chain amyloidosis.
    Absmeier RM; Rottenaicher GJ; Svilenov HL; Kazman P; Buchner J
    FEBS J; 2023 Mar; 290(6):1398-1419. PubMed ID: 35122394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of the elderly patient with AL amyloidosis.
    Nuvolone M; Milani P; Palladini G; Merlini G
    Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.
    Milani P; Fabris F; Mussinelli R; Sanna GD; Basset M; Benvenuti P; Bellofiore C; Nanci M; Nuvolone M; Attanasio A; Guida G; Perlini S; Foli A; Merlini G; Palladini G
    Amyloid; 2024 Sep; 31(3):220-225. PubMed ID: 38989681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.